Another monoclonal antibody for Alzheimer’s to get FDA review By / On July 13, 2022 / At 6:40 pm / In Chemical world 11 Views Some scientists aren’t hopeful that lecanemab, following in the footsteps of its unsuccessful predecessor, will shake things up Post navigation Prev PostChemistry in Pictures: Separation fascination Next PostSwitch to safer basic chemicals, activists tell industry You May Also Like Time-resolved spectroscopy shines new light on migratory insertion mechanism On August 8, 2022 | In Chemical world How can companies recycle wind turbine blades? On August 8, 2022 | In Chemical world A groundhog surprise and creative out-of-office replies On August 8, 2022 | In Chemical world